Levetiracetam
Product Images NDC 58118-1112

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 58118-1112). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Clinical Solutions Wholesale, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (5a86abbc 0e78 40d3 9ae6 F0cc78815cb5 01)

This text appears to be a formula for calculating the total daily dosage of a medication based on the patient's weight and the daily dose (in mg/kg/day) of the medication. The medication is in a concentration of 100 mg/mL.*

FDA Label Image

Figure 2 (5a86abbc 0e78 40d3 9ae6 F0cc78815cb5 02)

This appears to be a mathematical formula used to calculate the estimated creatinine clearance of female patients based on their age in years, weight in kilograms, and serum creatinine levels in milligrams per deciliter (mg/dL). The formula takes into account body surface area and involves adjusting CLer (creatinine clearance) in milliliters per minute (mL/min) to CLer (per 1.73 square meters) using the subject's body surface area (BSA) in square meters (m²).*

FDA Label Image

Structure (5a86abbc 0e78 40d3 9ae6 F0cc78815cb5 03)

FDA Label Image

Figure 4 (5a86abbc 0e78 40d3 9ae6 F0cc78815cb5 04)

This appears to be a chart with percentage values representing dosages of Levetiracetam (a medication used to treat epilepsy) for two groups of people (N=95 and N=97) taking either 1000mg/day or 3000mg/day. Without further context, it is not clear what the chart is showing or comparing.*

FDA Label Image

Figure 5 (5a86abbc 0e78 40d3 9ae6 F0cc78815cb5 05)

This appears to be a table showing the percentages of patients in a study who received a placebo or different doses of a medication called Levetiracetam. The percentages correspond to different levels of improvement in the patients' condition. There is not enough information to determine what condition the medication was meant to treat or any other details about the study.*

FDA Label Image

Figure 6 (5a86abbc 0e78 40d3 9ae6 F0cc78815cb5 06)

FDA Label Image

Figure 7 (5a86abbc 0e78 40d3 9ae6 F0cc78815cb5 07)

This is a tabular representation showing the percentage distribution of patients involved in Placebo and Levetiracetam groups. It is not clear what the percentages represent as the headings of the columns and rows are not available.*

FDA Label Image

Figure 8 (5a86abbc 0e78 40d3 9ae6 F0cc78815cb5 08)

This text provides the percentage of patients who received either placebo or Levetiracetam medication. 19.6% of the patients, a total number of 51, were given placebo, while 43.1% of patients, a total number of 58, were given Levetiracetam.*

FDA Label Image

Figure 9 (5a86abbc 0e78 40d3 9ae6 F0cc78815cb5 09)

This appears to be a graph or chart displaying the percentage of patients on a treatment, with the treatments being Placebo and Levetiracetam. The graph shows percentages ranging from 0 to 100%, with various values listed such as 45.2% and 72.2%. There is not enough context to determine what specific condition or ailment the treatments were for, or what exactly the percentages represent.*

FDA Label Image

Levetiracetam 250mg Tablets

This appears to be wholesale information for purchasing Evetiracetam 250mg Tablets with NDC code 58118-1112-8. The quantity available is 30, and the price is not mentioned. The manufacturer is Lupin Pharmaceuticals Inc. with a lot number of SAMPLE123 and batch number of SAMPLE4S6, which expires on September 2021. The location mentioned is Batmore, WD, USA, 21202, with a SN of WMMODO00000.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.